by Zoe Hogue | Jan 30, 2026 | Blog
Introduction While much attention has focused on the GLP-1 revolution in weight loss, a quieter transformation is unfolding in cardiology.In 2026, cardiovascular disease remains the leading cause of death worldwide. However, peptide therapeutics are moving far...
by Zoe Hogue | Jan 30, 2026 | Blog
Introduction For decades, the central nervous system (CNS) represented the final frontier of pharmaceutical treatment.Diseases such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS) remained difficult to treat due to one major obstacle:...
by Zoe Hogue | Jan 29, 2026 | Blog
Introduction In 2026, cancer treatment has reached a critical turning point.While chemotherapy and radiation remain foundational, they often act as blunt instruments. Healthy tissue suffers alongside the tumor. Peptide-based cancer therapeutics are changing that...
by Zoe Hogue | Jan 29, 2026 | Blog
Introduction In 2026, the obesity conversation officially changed.The focus shifted from willpower to biology. At the center of this shift is GLP-1 (Glucagon-Like Peptide-1). Originally identified as a gut hormone, GLP-1 now powers the most in-demand weight-loss...
by Zoe Hogue | Jan 29, 2026 | Blog
The Two-Tiered Peptide Market Structure The peptide therapeutics market follows a clear two-tier structure.Innovative (branded) peptides, protected by patents, command premium pricing and dominate market share. Generic and biosimilar peptides enter after...
by Zoe Hogue | Jan 29, 2026 | Blog
Global Peptide Therapeutics Market Size: $260B by 2030 Market Trajectory: From $117B to $260B The global peptide therapeutics market stands poised for remarkable expansion, with valuations projected to more than double from $117.26 billion in 2024 to $260.25 billion...
